Project Grant R01CA296280
Award Date
12/1/24
Completion Date
11/30/29
Dollars Obligated
$1.5M
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Irwindale, CA 91010, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to harness B cells after stem cell transplant to produce novel chimeric antigen receptor T-cells (CAR-Ts) for treating hematological malignancies. The $415,257 award to Duke University, a leading research institution, will fund research to clone antibody-producing B cells with tumor-binding potential after hematopoietic stem cell transplantation. The goal is to engineer less toxic and...
This $1,108,391.72 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research to define the most therapeutically relevant chimeric antigen receptor (CAR) T cell subsets for treating large B cell lymphoma (LBCL) and overcome immune suppression mechanisms that limit CAR T cell efficacy. The funded project will use a systems biology approach to analyze patient data and pinpoint optimal CAR T cell characteristics for...
The National Cancer Institute (NCI) awarded a $222,998 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of California, San Diego (UCSD) for the period of March 10, 2025 to February 28, 2027. The grant supports research to engineer endogenous immune cells, including T cells, NK cells, and macrophages, to express chimeric antigen receptors (CARs) using a novel virus-like particle (VLP) vector. The goal is to enable these engineered immune cells to mediate...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $457,683 to the Beckman Research Institute of the City of Hope to develop and evaluate novel "Bio-Beacons" - tumor-targeting bacterial vectors engineered to secrete chemokines and cytokines. The goal is to increase the density of tumor-reactive immune cells, such as CD8 T cells, CD4 T cells, dendritic cells, and natural killer cells, within solid tumors. This is...
The National Cancer Institute (NCI), under the federal Cancer Treatment Research Grant Program (CFDA 93.395), awarded a $398,997 Project Grant to Immunogenik, Inc. in Gainesville, Florida. The grant supports the development and evaluation of a "3-in-1" Chimeric Antigen Receptor (CAR) T-cell therapy to enhance cancer treatment. The project aims to overcome limitations of current cancer therapies by targeting tumor-associated myeloid cells, which play a key role in cancer...
The National Cancer Institute (NCI), through the Cancer Treatment Research program (CFDA 93.395), awarded a $1,999,703 project grant to March Biosciences Inc. to develop dual-targeting allogeneic chimeric antigen receptor (CAR) T-cell therapies for the treatment of relapsed and refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoma (TCL). The 2-year project aims to engineer partially-matched donor-derived CAR-T cells targeting both CD5 and CD7 antigens, which are expressed in...
The National Cancer Institute (NCI), through the Cancer Treatment Research Federal Grant Program (CFDA 93.395), awarded a $1,220,394 project grant to the Sloan-Kettering Institute for Cancer Research in New York. The 5-year grant, awarded on September 15, 2024, will fund research to comprehensively characterize the acute and chronic neurotoxicity associated with chimeric antigen receptor (CAR) T-cell therapy for hematologic malignancies. The research aims to investigate the molecular...
The National Cancer Institute (NCI) awarded a $208,103 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the Beckman Research Institute of the City of Hope, a nonprofit medical research organization. This 5-year grant, effective September 1, 2024, will support the research activities of Dr. Alex Herrera as a Clinical and Translational Lymphoma Investigator. Through this grant, Dr. Herrera will lead efforts to: (1) build specialized clinical research infrastructure to...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the Beckman Research Institute of the City of Hope provides $738,698 to develop a novel combination therapy for treating relapsed and refractory acute myelogenous leukemia (AML) in older patients. The key product being developed is a targeted radiotherapy approach that combines total marrow irradiation (TMLI) with an anti-CD38 targeted alpha therapy (TAT) using the monoclonal antibody...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $249,645 to Boston Children's Hospital to develop advanced genetic engineering techniques to study the role of tumor-specific B cells in cancer progression. The researchers aim to genetically modify B cells to target the HER2 tumor antigen, with the goal of using these engineered B cells as an adoptive immunotherapy to trigger both humoral and cellular anti-tumor immune responses. The...